Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin eicosapentaenoate
- Development stage
- Phase 1
- Lead developer
- Thetis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metformin eicosapentaenoate is an orally administered small-molecule salt pairing **metformin** with **eicosapentaenoic acid** as eicosapentaenoate, developed by Thetis Pharmaceuticals as TP-101. It was investigated as a solid oral dosage form intended to deliver the glucose-lowering pharmacology of metformin together with the lipid-modulating effects associated with eicosapentaenoic acid for type 2 diabetes mellitus and hypertriglyceridemia. A completed Phase 1 study compared its pharmacokinetics, safety, and tolerability with separately co-administered metformin hydrochloride and icosapent ethyl under fed and fasted conditions; the published PK analysis reported no pharmacokinetic advantage over separate administration.
- Other names
- CG73ERQ805CG-73ERQ805CG 73ERQ805metformin eicosapentaenoatemetformin epametformin icosapentUNII-CG73ERQ805UNII-CG-73ERQ805UNII-CG 73ERQ805
02
Targets
ND1 (Mitochondrial electron transport chain complex I)PRKAB1 (AMPK β1)TBXAS1 (Thromboxane A2 synthase)FFAR4 (Free fatty acid receptor 4)NADH:ubiquinone oxidoreductase subunit family
Beyond the preview
Go deeper on metformin eicosapentaenoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin eicosapentaenoate.